Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Apremilast 30mg tablets
1001030AAAAAAAA
|
Apremilast | Apremilast | Musculoskeletal and Joint Diseases | 31 |
|
Baricitinib 4mg tablets
1001030ACAAAAAA
|
Baricitinib | Baricitinib | Musculoskeletal and Joint Diseases | 29 |
|
Nurofen for Children 200mg/5ml oral suspension strawberry
1001010J0B4BDBR
|
Nurofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 28 |
|
Calprofen 100mg/5ml oral suspension
1001010J0DBAABH
|
Calprofen | Ibuprofen | Musculoskeletal and Joint Diseases | 27 |
|
Naproxen 200mg/5ml oral suspension
1001010P0AABCBC
|
Naproxen | Naproxen | Musculoskeletal and Joint Diseases | 27 |
|
Hydroxychloroquine 100mg/5ml oral liquid
1001030C0AAAFAF
|
Hydroxychloroquine sulfate | Hydroxychloroquine sulfate | Musculoskeletal and Joint Diseases | 26 |
|
Methofill 17.5mg/0.35ml inj pre-filled syringes
1001030U0BGANBL
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 26 |
|
Pyridostigmine bromide 30mg/5ml oral suspension
1002010Q0AABHBH
|
Pyridostigmine bromide | Pyridostigmine bromide | Musculoskeletal and Joint Diseases | 25 |
|
Ibuprofen Seven Plus Pain Relief 200mg/5ml oral suspension
1001010J0DKABBR
|
Ibuprofen Plus Pain Relief | Ibuprofen | Musculoskeletal and Joint Diseases | 24 |
|
Nurofen for Children 200mg/5ml oral suspension orange
1001010J0B4BCBR
|
Nurofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 24 |
|
Glucosamine hydrochloride 600mg capsules
1001050A0AAAPAP
|
Glucosamine hydrochloride | Glucosamine hydrochloride (Rheumatic) | Musculoskeletal and Joint Diseases | 23 |
|
Methotrexate 30mg/0.6ml inj pre-filled disposable devices
1001030U0AACACA
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 23 |
|
Neostigmine 15mg tablets
1002010M0AAAAAA
|
Neostigmine bromide | Neostigmine bromide | Musculoskeletal and Joint Diseases | 23 |
|
Nurofen Long Lasting Pain Relief PR 300mg capsules
1001010J0B4ANAB
|
Nurofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 23 |
|
Pridinol 3mg tablets
1002020Z0AAAAAA
|
Pridinol mesilate | Pridinol mesilate | Musculoskeletal and Joint Diseases | 23 |
|
Ibuleve Speed Relief Max Strength 10% gel
1003020P0BCAIAI
|
Ibuleve | Ibuprofen | Musculoskeletal and Joint Diseases | 22 |
|
Ibuleve Speed Relief 5% spray
1003020P0BCAHAD
|
Ibuleve | Ibuprofen | Musculoskeletal and Joint Diseases | 21 |
|
Indometacin 25mg/5ml oral solution
1001010K0AAAQAQ
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | 21 |
|
Surgam 300mg tablets
1001010T0BBABAC
|
Surgam | Tiaprofenic acid | Musculoskeletal and Joint Diseases | 21 |
|
Diclo-SR 75mg tablets
1001010C0CRAAAL
|
Diclo-SR | Diclofenac sodium | Musculoskeletal and Joint Diseases | 20 |
|
Ibuprofen 100mg/5ml oral suspension 5ml sachets sugar free
1001010J0AABMBM
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 20 |
|
Keral 25mg tablets
1001010AEBBAAAA
|
Keral | Dexketoprofen | Musculoskeletal and Joint Diseases | 19 |
|
Methofill 12.5mg/0.25ml inj pre-filled syringes
1001030U0BGAUBK
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 19 |
|
Pyridostigmine bromide 180mg modified-release tablets
1002010Q0AABKBK
|
Pyridostigmine bromide | Pyridostigmine bromide | Musculoskeletal and Joint Diseases | 19 |
|
Diclofenac 75mg/1ml solution for injection ampoules
1001010C0AABMBM
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 18 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.